MediWound Ltd.

NASDAQ:MDWD

Biotechnology

Healthcare
$13.68 -0.60%

-$0.09 today

Market cap
$176.61M
Beta
0.15
P/E (TTM)
-7.0
EPS (TTM)
-$2.03
52W Low $13.54High $21.26

Volume 0.16M

Average 0.09M

MDWD Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

MediWound Ltd.NASDAQ: MDWD

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 21.9%

Gross margin was 21.9% in Q1 FY2026, up 3.2 pp from a year earlier. On a trailing-twelve-month basis it was 19.6%, up 5.2 pp year over year. Over 3 fiscal years it narrowed by 30.5 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
21.9%+7.0 pp QoQ
Last fiscal yearDec 2025
19.2%+6.2 pp YoY
LTMMar 2026
19.6%+5.2 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+3.2 pp——
1 year+6.2 pp——
3 years-30.5 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
19.2%
Year-over-year change
+6.2pp

Gross Margin vs competitors

How MDWD compares with its peers on the latest reported figures

  • MDWD's LTM Mar 2026 gross margin of 19.6% is the 5th highest of the 6 companies compared; the peer median is 92.0%.
  • Its year-over-year change of +5.2 pp is the 2nd highest of 5, against a peer median of -33.8 pp.
  • Over three fiscal years its change of -30.5 pp compares with a peer median of +1.8 pp.
MDWD Competitors Peer median
Gross Margin for MDWD and competitors
Company Period LTM level YoY 3-year change
NTHINeonc Technologies Holdings, Inc.FY2025100.0% ——
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 202699.3% +6.7 pp+8.5 pp
IVVDInvivyd, Inc.LTM Mar 202692.0% -1.3 pp—
IVAInventiva S.A.FY202533.7% -66.3 pp-106.4 pp
MDWDMediWound Ltd.LTM Mar 202619.6% +5.2 pp-30.5 pp
RNACCartesian Therapeutics, Inc.LTM Mar 2026-621.0% -721.0 pp+1.8 pp
SLSSELLAS Life Sciences Group, Inc.FY2025— ——
EPRXEupraxia Pharmaceuticals Inc.FY2025— ——
TARAProtara Therapeutics, Inc.FY2025— ——
AARDAardvark Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding MDWD) 92.0%-33.8 pp+1.8 pp

Competitors are the stored peer set for MDWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue23.76M26.5M18.69M20.22M16.96M
Cost of Revenue14.99M13.33M15.11M17.59M13.71M
Gross Profit8.77M13.17M3.58M2.63M3.25M
Gross Margin36.9%49.7%19.1%13.0%19.2%
Research & Development10.26M10.18M7.47M8.88M14.32M
Selling, General & Admin9.45M10.37M11.38M12.91M13.93M
Operating Expenses19.99M20.83M19.08M22.02M28.53M
Depreciation & Amortization1.24M1.27M1.3M1.48M1.86M
EBITDA(11.38M)(18.25M)(4.8M)(27.93M)(21.47M)
EBITDA Margin-47.9%-68.9%-25.7%-138.1%-126.6%
Operating Income(11.22M)(7.66M)(15.5M)(19.38M)(25.28M)
Operating Margin-47.2%-28.9%-83.0%-95.8%-149.1%
Interest Income11K270K2.34M2.05M1.86M
Interest Expense167K162K335K561K663K
Other Income / Expenses(2.3M)(11.86M)8.97M(10.78M)1.57M
Income Before Tax(13.52M)(19.52M)(6.53M)(30.16M)(23.71M)
Pre-Tax Margin-56.9%-73.7%-35.0%-149.2%-139.8%
Income Tax Expense27K78K185K61K169K
Net Income(13.55M)(19.6M)(6.72M)(30.22M)(23.88M)
Net Margin-57.0%-74.0%-35.9%-149.5%-140.8%
EPS (Basic)(3.48)(3.93)(0.75)(3.03)(2.10)
EPS (Diluted)(3.48)(3.93)(0.75)(3.03)(2.10)
Weighted Avg Shares3.89M4.99M9.01M9.96M11.38M
Weighted Avg Shares (Diluted)3.89M4.99M9.01M9.96M11.38M

MediWound Ltd.

NASDAQ:MDWD

Intrinsic Alpha fair value

Locked

Current Price

$13.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.